Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IA dose-escalation study of oral BKM120 in advanced solid malignancies
NL-OMON35139Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buparlisib in Nonhematologic neoplasms, cancer and metastasis, sponsored by Novartis. Primary endpoint: Maximum tolerated dose. Started Jun 2009; status: active, not recruiting.
02
Drugs
buparlisib
03
Conditions
Nonhematologic neoplasmscancermetastasis
Beyond the preview
Go deeper on NL-OMON35139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35139.